Omnitrope 6.7 mg/ml solution for injection

ATC Code
Medikamio Hero Image

About this drug

Admission country
Manufacturer Sandoz GmbH
Narcotic drug No
Psychotropic No
Anatomical group Systemische hormonpräparate, exkl. sexualhormone und insuline
Therapeutic group Hypophysen- und hypothalamushormone und analoga
Pharmacological group Hypophysenvorderlappenhormone und analoga
Chemical group Somatropin und somatropinrezeptoragonisten
Substance Somatropin


All to know


Sandoz GmbH

What is it?

Omnitrope is a medicine containing the active substance somatropin. It is available as a powder and solvent, which are made up into a solution for injection (1.3 or 5 mg/ml), or as a ready-to-use solution in a cartridge (3.3 or 6.7 mg/ml).
Omnitrope is a ?biosimilar? medicine. This means that Omnitrope is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ?reference medicine?). The reference medicine for Omnitrope is Genotropin. For more information on biosimilar medicines, see the question-and-answer document here.

What is it used for?

Omnitrope is used to treat children:

  • who have trouble with their growth because they do not have enough growth hormone (GH),
  • when they are short because they have chronic renal insufficiency (malfunctioning kidneys) or a genetic disorder called Turner syndrome,
  • when they are short, because they were born small for their gestational age, and have not caught up by the age of four years or later,
  • when they have a genetic condition called Prader-Willi syndrome. Omnitrope is given to improve their growth and their body composition (relationship of fat and muscle mass). The diagnosis must be confirmed by appropriate genetic testing. Omnitrope is also used to treat adult patients with pronounced GH deficiency as replacement therapy.The medicine can only be obtained with a prescription.


How is it used?

Omnitrope treatment should be supervised by a doctor experienced in the management of patients with growth disorders. Omnitrope is given by subcutaneous injection (under the skin), once a day at bedtime. The patient or caregiver can inject Omnitrope themselves, after training by a doctor or a nurse. The Omnitrope cartridges should only be used with the special Omnitrope injection device. The doctor calculates the dose for each patient individually, depending on the body weight and the condition being treated. The dose may need to be adjusted over time, depending on change in body weight and response.

How does it work?

GH is a substance secreted by the pituitary gland (a gland located at the base of the brain). It promotes growth during childhood and adolescence, and also acts on the way the body handles proteins, fat and carbohydrates. The active substance in Omnitrope, somatropin, is identical to the human GH. It is produced by a method known as ?recombinant DNA technology?: the hormone is made by a bacterium which has received a gene (DNA) that makes it able to produce it. Omnitrope replaces the natural hormone.

How has it been studied?

Omnitrope was studied to show that it is comparable to the reference medicine, Genotropin. Omnitrope was compared to Genotropin in 89 children with a lack of GH and who had not been treated before. The study lasted nine months, and measured the height at the beginning and the end of the study, and the speed of growth during the study. To study the safety of Omnitrope, another 51 children have also received the medicine for up to a year.

What benefits has it shown during the studies?

After nine months, treatment with Omnitrope and Genotropin gave similar increases in height and speed of growth (equivalent to an increase of 10.7 cm per year with both medicines). The effectiveness of Omnitrope has been shown to be equivalent to that of Genotropin.

What is the risk associated?

The side effects seen with Omnitrope were similar in type and severity to those seen with the reference medicine Genotropin. The most common side effects (seen in between 1 and 10 patients in 100) are, in children, transient local skin reactions at the site of injection, and in adults, mild oedema (accumulation of fluid), paraesthesia (numbness or tingling), joint and muscle pain (especially in the hip or knee) and stiffness of the limbs. In addition, as with all protein medicines, some patients may develop antibodies (proteins that are produced in response to Omnitrope). However these have no growth-inhibiting effects. For the full list of all side effects reported with Omnitrope, see the Package Leaflet.
Omnitrope should not be used in people who may be hypersensitive (allergic) to somatropin or any of the other ingredients (the ready-to-use solution and the solvent for Omnitrope 5 mg/ml contain benzyl alcohol). Omnitrope should not be used when the patient suffers from an active tumour or an acute life-threatening illness. For the full list of restrictions, see the Package Leaflet.
Somatropin may interfere with the body?s use of insulin. Blood sugar levels will need to be checked during treatment, and treatment with insulin may sometimes need to be adjusted or started.

Why has it been approved?

The Committee for Medicinal products for Human Use (CHMP) considered that, in accordance with EU requirements, Omnitrope has been shown to have a comparable quality, safety and efficacy profile to Genotropin. Therefore, the CHMP?s view was that, as for Genotropin, the benefit outweighs the identified risk.



Your personal medicine assistent


Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.

This website is certified by Health On the Net Foundation. Click to verify.